About
Brink Biologics develops and licenses standardized NK-92 natural killer cell lines and related assays used primarily for antibody-dependent cellular cytotoxicity (ADCC) testing and immunological research in therapeutic development.
Explore Brink Biologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.